MitoRx Therapeutics Expands Leadership Team with Strategic Appointments of Chief Business Officer and Finance Director
Oxford, England, 9th January 2025 – MitoRx Therapeutics (MitoRx), a platform biotechnology company developing novel mitochondrial-targeted sulfide-donor therapeutics (mtH2SD) in obesity-related disorders and myopathies announces the appointments of Dr. Lubor Gaal as Chief Business Officer (CBO) and Stacey Massey as Finance Director. These key leadership additions reinforce MitoRx’s commitment to advancing its innovative programs including its obesity program offering weight loss with muscle protection and scaling its operations to address significant unmet medical needs.
